# Wellington Management

> Wellington Management is a VC fund backing Biotechnology and Health Care. See 292 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Boston, United States
- Total investments: 292
- Last investment: Aug 2026
- Lead investor: 32%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/wellington-management
- X (Twitter): https://twitter.com/wellingtonmgt
- Website: http://wellington.com
- Facebook: https://www.facebook.com/pages/Wellington-Management-Inc/192813427434277

Wellington Management is a VC fund in Boston focused on Biotechnology and Health Care. Wellington Management focuses on investment management. The company applies its full resources to meet the needs of the institutional clients they serve. Their investment approaches span equity, fixed income, currency, commodity, and alternative markets. They also offer asset allocation, multi-manager, and speciality approaches.

## Contacts

5 contacts available for Wellington Management. Shizune tracks 12 team members at Wellington Management. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/wellington-management?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 84 | 29% |
| Health Care | 69 | 24% |
| Medical | 47 | 16% |
| Therapeutics | 34 | 12% |
| Pharmaceutical | 29 | 10% |

233 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 53 | 18% |
| Series B | 45 | 15% |
| Post-IPO Equity | 36 | 12% |
| Series D | 32 | 11% |
| Series E | 24 | 8% |

18 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 190 | 65% |
| United Kingdom | 9 | 3% |
| India | 8 | 3% |
| Israel | 4 | 1% |
| Germany | 4 | 1% |

17 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Jean Hynes | CEO, Managing Partner, and Portfolio Manager | 0 | https://shizune.co/investors/profile/jean-hynes-51a3 |
| Jackson Cummings | Head of Diverse Founders Investing | 4 | https://shizune.co/investors/profile/jackson-cummings |
| Joshua Sommerfeld | Private Equity Principal | 2 | https://shizune.co/investors/profile/josh-sommerfeld |
| Matthew Witheiler | Private Equity | 13 | https://shizune.co/investors/profile/matthew-witheiler |
| Melissa Marquis | Manager, Currency Trading Technology | 0 | https://shizune.co/investors/profile/melissa-marquis |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Whatnot | Whatnot is a Los Angeles-based startup that creates a place where avid collectors could come together over shared interests. Whatnot is a marketplace to buy and sell authentic collectible items. Whatnot was founded in 2019, in California. | $545M | Series G | Aug 06, 2026 |  |
| Tarsus Pharmaceuticals | Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases acrosstherapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis. | $125M | Post-IPO Equity | Aug 06, 2026 |  |
| Obsidian Therapeutics | Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer.The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with newfunctions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies. | $350M | Post-IPO Equity | Aug 04, 2026 |  |
| Crystalys Therapeutics | Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout. | $130M | Series B | Jul 22, 2026 |  |
| Flex | Flex is a financial technology company that offers an end-to-end finance platform that integrates business and personal finance management. Their services include business banking with zero monthly fees, 1% cashback on eligible purchases, and high-yield accounts with up to 2.99% APY on idle cash. They provide a business credit card featuring 0%interest for 60 days on eligible purchases, unlimited cashback, and flexible rewards. Flex also offers accounts payable automation with features like fraud prevention, AI-powered bill scanning, and real-time payment tracking. Additionally, their platform supports global payments across over 180 countries in 32 currencies, catering to businesses with international operations. | $70M | Series B | Jul 14, 2026 |  |
| Fore Biotherapeutics | We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. | $67.4M | Series D | Jul 07, 2026 |  |
| Quantum Systems | Quantum Systems provides AI-powered aerial intelligence solutions for defense and emergency services. The company designs and develops advanced aerial systems equipped with artificial intelligence to gather, analyze, and interpret data for strategic decision-making. These solutions are particularly valuable for surveillance, monitoring, andreal-time information processing, enabling clients to enhance operational efficiency, safety, and effectiveness in critical operations. | $1.2B | Series D | Jul 02, 2026 |  |
| Higharc | Higharc is the all-in-one web platform that simplifies, connects, and improves each step of design, construction, and sales for home building. It enables builders to design, sell in 3D, and get permit-ready construction documents — all in a single platform. Higharc is on a mission to help builders create better homes and communities, moreaffordably. | $95M | Series C | Jun 30, 2026 |  |
| RQ Bio | RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza with the goal of providing immediate, powerful, and long-lasting protection against severe viral disease in immunocompromised and high-risk subjects. The company's mission is to deliver "instant immunity" through passiveimmunization, helping protect vulnerable populations such as the elderly, newborns, and immunocompromised patients from severe infectious diseases. The company specializes in the discovery and development of broad-spectrum antiviral antibodies that are engineered to remain effective even as viruses evolve. Its scientific approach combines virology, antibody engineering, computational biology, and immune-directed discovery techniques to identify potent antibodies that target conserved regions of viral proteins, reducing the risk of resistance caused by viral mutations.RQ Bio's lead programs focus on infectious diseases such as influenza, COVID-19, respiratory syncytial virus (RSV), and cytomegalovirus (CMV). The company is currently developing long-acting monoclonal antibodies designed to provide once-yearly protection against seasonal influenza, particularly for individuals at high risk of severe disease. | $112.5M | Series A | Jun 24, 2026 |  |
| Baseten | Baseten provides a platform for training, deploying, and serving artificial intelligence models in production environments. It supports open-source, fine-tuned, and custom models, converting them into API endpoints with capabilities such as autoscaling, observability, and optimized model serving. The platform manages infrastructure componentsincluding containerization, GPU scheduling across multiple cloud providers, and performance optimizations to support large-scale inference workloads. Baseten also offers preconfigured model APIs and deployment options that can run either on its managed cloud service or within a customer's own environment. Its tools are designed to help developers build, manage, and scale AI applications while maintaining flexibility in how models are hosted and executed. | $1.5B | Series F | Jun 22, 2026 |  |

10 of 292 investments shown.

## Co-investors
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 36 deals together
- [Janus Henderson Investors](https://shizune.co/investors/profile/janus-henderson-investors) — VC Fund, 34 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 31 deals together
- [Logos Capital](https://shizune.co/investors/profile/logos-capital) — VC Fund, 29 deals together
- [Fidelity](https://shizune.co/investors/profile/fidelity-investments) — VC Fund, 28 deals together
- [T. Rowe Price](https://shizune.co/investors/profile/t-rowe-price) — VC Fund, 28 deals together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Wellington Management invest in?

Wellington Management invests primarily in Biotechnology, Health Care and Medical startups, most often at Series C and Series B stage. Most of the 292 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Wellington Management?

Public channels for Wellington Management include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Wellington Management?

The team at Wellington Management includes Jean Hynes (CEO, Managing Partner, and Portfolio Manager), Jackson Cummings (Head of Diverse Founders Investing) and Joshua Sommerfeld (Private Equity Principal), among 12 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co